Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines
- PMID: 15035290
- DOI: 10.3171/jns.2004.100.3.0523
Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines
Abstract
Object: Quantitative and qualitative alterations in the epidermal growth factor receptor (EGFR) commonly occur in many cancers in humans, including malignant gliomas. The aim of the current study was to evaluate molecular and cellular effects of OSI-774, a novel EGFR tyrosine kinase inhibitor, on nine glioblastoma multiforme (GBM) cell lines.
Methods: The effects of OSI-774 on expression of EGFR messenger (m)RNA and protein, proliferation, anchorage-independent growth, and apoptosis were examined using semiquantitative reverse transcription-polymerase chain reaction, immunocytochemical analysis, Coulter counting, soft agar cloning, and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling/fluorescence-activated cell sorting, respectively. All p53 genes were completely and bidirectionally sequenced. Suppression of anchorage-independent growth by OSI-774 was inversely correlated to the induction of EGFR mRNA during relative serum starvation (r = -0.74) and was unrelated to p53 status. Overall, suppression of anchorage-independent growth was a considerably stronger effect of OSI-774 than inhibition of proliferation. The extent of OSI-774-induced apoptosis positively correlated with both proliferation and anchorage-independent growth of GBM cell lines (r = 0.75 and 0.79, respectively). In a single cell line derived from a secondary GBM, exposure to concentrations of greater than or equal to 1 micromol/L resulted in a substantial net cell loss during proliferation studies.
Conclusions: The induction of EGFR mRNA may constitute a cellular mechanism to counteract the inhibitory effect of OSI-774 on the anchorage-independent growth of GBM cells. In contrast, no considerable correlation could be established between baseline expression levels of EGFR (both mRNA and protein) in GBM cell lines and their biological response to OSI-774. The OSI-774 induced greater (p53-independent) apoptosis in more malignant GBM phenotypes and may be a promising therapeutic agent against secondary GBM.
Similar articles
-
Epidermal growth factor receptor pathway gene expressions and biological response of glioblastoma multiforme cell lines to erlotinib.Anticancer Res. 2008 Nov-Dec;28(6A):3725-8. Anticancer Res. 2008. PMID: 19189656
-
Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.Anticancer Drugs. 2006 Aug;17(7):783-95. doi: 10.1097/01.cad.0000217433.48870.37. Anticancer Drugs. 2006. PMID: 16926628
-
HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.J Neurooncol. 2005 Aug;74(1):77-86. doi: 10.1007/s11060-005-0603-7. J Neurooncol. 2005. PMID: 16078112 Review.
-
Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774.Biochem Pharmacol. 2004 May 1;67(9):1689-700. doi: 10.1016/j.bcp.2003.12.035. Biochem Pharmacol. 2004. PMID: 15081868
-
Development of the epidermal growth factor receptor inhibitor OSI-774.Semin Oncol. 2003 Jun;30(3 Suppl 6):23-31. doi: 10.1016/s0093-7754(03)70022-0. Semin Oncol. 2003. PMID: 12802792 Review.
Cited by
-
Glioblastoma Therapy: Past, Present and Future.Int J Mol Sci. 2024 Feb 21;25(5):2529. doi: 10.3390/ijms25052529. Int J Mol Sci. 2024. PMID: 38473776 Free PMC article. Review.
-
Special Issue: Principal Challenges in the Adjuvant Treatment of Glioblastoma.Biomedicines. 2023 Jul 3;11(7):1881. doi: 10.3390/biomedicines11071881. Biomedicines. 2023. PMID: 37509520 Free PMC article.
-
Effectively utilizing publicly available databases for cancer target evaluation.NAR Cancer. 2023 Jul 14;5(3):zcad035. doi: 10.1093/narcan/zcad035. eCollection 2023 Sep. NAR Cancer. 2023. PMID: 37457379 Free PMC article.
-
Recurrent Glioblastoma Treatment: State of the Art and Future Perspectives in the Precision Medicine Era.Biomedicines. 2022 Aug 9;10(8):1927. doi: 10.3390/biomedicines10081927. Biomedicines. 2022. PMID: 36009473 Free PMC article. Review.
-
Identification of TNFAIP6 as a hub gene associated with the progression of glioblastoma by weighted gene co-expression network analysis.IET Syst Biol. 2022 Sep;16(5):145-156. doi: 10.1049/syb2.12046. Epub 2022 Jun 29. IET Syst Biol. 2022. PMID: 35766985 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous